Chloroquine-induced Itch is Mediated by Mrgs

Case ID:
C10519
Disclosure Date:
10/20/2008

C10519: Methods and Compositions for Treating Itch


Value Proposition:

Inventors have identified a cell receptor family known as Mrgprs that is exclusively expressed in a small subset of neurons. In vitro and animal studies suggest that the Mrg receptor family directly mediates chloroquine (CQ) induced itch. Identification and characterization of Mrgprs may now provide molecular access to itch-selective neurons and constitute novel targets for itch therapeutics.

ADVANTAGES
- Researchers have identified a receptor for chloroquine-induced itch which may speed discovery and development of therapeutic agents to reduce itch side effects.
- A newly developed anti-itch drug would reduce side effects of chloroquine treatment of malaria patients to increase patient quality of life and treatment compliance, which is a recognized problem of malaria patients.

Technical Details:

Probably few things are more maddening than a persistant itching sensation. Whether due to allergic reaction, insect bite or a side effect of medication, those needing relief from itch is a large population. Available therapeutic products are not always as effective as necessary. Unfortunately, our knowledge of itch mechanisms at cellular and molecular levels is poor. An example of a medically recognized itch problem is a side effect of a malaria therapeutic compound known as chloroquine (CQ). In some cases, the chloroquine-induced itch is so severe that patients are reluctant to take CQ as prescribed. There is a significant unmet need for development of agents and method to reduce itch.

- Liu et al, Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell. 2009 Dec 24;139(7):1353-65. Epub 2009 Dec 10.

Looking for Partners:

This discovery could be commercialized as therapeutic agents that modulate activity or expression of Mrg receptors that cause itch. In addition, this invention could potentially be commercialized as a molecular tool to screen candidate agents as treatments for histamine-independent or chloroquine-induced itch.




Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Methods and Compositions for Treating or Preventing Pruritis DIV: Divisional United States 14/163,370 9,771,592 1/24/2014 9/26/2017 11/30/2029 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum